Download PDF
Horm Metab Res 2004; 36(11/12): 852-858
DOI: 10.1055/s-2004-826175
Review
© Georg Thieme Verlag KG Stuttgart · New York

Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes

M.  A.  Nauck1
  • 1 Diabeteszentrum Bad Lauterberg, Germany
Further Information

Publication History

Received 15 July 2004

Accepted without revision 5 August 2004

Publication Date:
18 January 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Glucagon-like peptide 1 (GLP-1) was discovered as an incretin (insulinotropic gut) hormone. Biological actions of GLP-1 in healthy and type 2 diabetic subjects include (a) stimulation of insulin secretion in a glucose-dependent manner, (b) suppression of glucagon, (c) reduction in appetite and food intake, (d) deceleration of gastric emptying. In animal experiments, in addition, (e) stimulation of β-cell neogenesis, growth and differentiation in animal and tissue culture experiments, and (f) in vitro inhibition of β-cell apoptosis induced by different agents have been observed. Since the incretin effect - the higher insulin secretory response to oral as compared to intravenous glucose loads - is reduced in patients with Type 2 diabetes, GLP-1 has been used to pharmacologically replace incretin. Intravenous GLP-1 can normalise, and subcutaneous GLP-1 can significantly lower plasma glucose in the majority of patients with Type 2 diabetes. The magnitude of this effect does not greatly depend on patient characteristics such as age, sex, obesity, or baseline insulin and glucagon, with minor influences of previous antidiabetic therapy and actual metabolic control. GLP-1 itself, however, is inactivated rapidly in vivo by the protease DPP IV and can only be used for short-term metabolic control, such as in intensive care units (potentially useful in patients with acute myocardial infarction, coronary surgery, cerebrovascular events, septicaemia, during the perioperative period and while on parenteral nutrition). For more long-term metabolic control, incretin mimetics (agonists at the GLP-1 receptor) with more favourable pharmacokinetic profiles should be used.

Key words

Glucagon-like peptide-1 - Incretin - Incretin mimetic - Type 2 diabetes - Insulin - Glucagon - β-cell - Obesity - Gastric emptying

References

  • 1 Schmidt W E, Siegel E G, Creutzfeldt W. Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets.  Diabetologia. 1985;  28 704-707
    CrossrefPubMedGoogle Scholar
  • 2 Holst J J, Ørskov C, Vagn-Nielsen O, Schwartz T W. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut.  FEBS Letters. 1987;  211 169-174
    CrossrefPubMedGoogle Scholar
  • 3 Mojsov S, Weir G C, Habener J F. Insulinotropin: glucagon-like peptide I (7 - 37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.  J Clin Invest. 1987;  79 616-619
    CrossrefPubMedGoogle Scholar
  • 4 Kreymann B, Williams G, Ghatei M A, Bloom S R. Glucagon-like peptide-1 7-36: a physiological incretin in man.  Lancet. 1987;  2 1300-1304
    PubMedGoogle Scholar
  • 5 Nauck M A, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.  J Clin Endocrinol Metab. 1993;  76 912-917
    CrossrefPubMedGoogle Scholar
  • 6 Nauck M A, Kleine N, Ørskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.  Diabetologia. 1993;  36 741-744
    CrossrefPubMedGoogle Scholar
  • 7 Nauck M A, Weber I, Bach I, Richter S, Ørskov C, Holst J J. et al . Normalization of fasting glycaemia by intravenous GLP-1 (7-36 amide or 7 - 37) in type 2 diabetic patients.  Diabetic Med. 1998;  15 937-945
    CrossrefPubMedGoogle Scholar
  • 8 Nauck M A, Sauerwald A, Ritzel R, Holst J J, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.  Diabetes Care. 1998;  21 1925-1931
    PubMedGoogle Scholar
  • 9 Meier J J, Gallwitz B, Salmen S, Goetze O, Holst J J, Schmidt W E. et al . Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2003;  88 2719-2725
    CrossrefPubMedGoogle Scholar
  • 10 Nauck M A, Heimesaat M M, Behle K, Holst J J, Nauck M S, Ritzel R. et al . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.  J Clin Endocrinol Metab. 2002;  87 1239-46
    CrossrefPubMedGoogle Scholar
  • 11 Qualmann C, Nauck M A, Holst J J, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.  Acta Diabetol. 1995;  32 13-16
    CrossrefPubMedGoogle Scholar
  • 12 Toft-Nielsen M, Madsbad S, Holst J J. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.  Diabetologia. 1998;  41 1180-1186
    CrossrefPubMedGoogle Scholar
  • 13 Quddusi S, Vahl T P, Hanson K, Prigeon R L, D’Alessio D A. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.  Diabetes Care. 2003;  26 791-798
    PubMedGoogle Scholar
  • 14 Meier S, Hücking K, Ritzel R, Holst J J, Schmiegel W H, Nauck M A. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.  Horm Metab Res. 2003;  35(9) 551-556
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hvidberg A, Nielsen M T, Hilsted J, Ørskov C, Holst J J. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man.  Metabolism. 1994;  43 104-108
    CrossrefPubMedGoogle Scholar
  • 16 Nauck M A, Heimesaat M M, Ørskov C, Holst J J, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.  J Clin Invest. 1993;  91 301-307
    CrossrefPubMedGoogle Scholar
  • 17 Wettergren A, Schjoldager B, Mortensen P E, Myhre J, Christiansen J, Holst J J. Truncated GLP-1 (proglucagon 78 - 107-amide) inhibits gastric and pancreatic functions in man.  Dig Dis Sci. 1993;  38 665-673
    CrossrefPubMedGoogle Scholar
  • 18 Nauck M A, Niedereichholz U, Ettler R, Holst J J, Ørskov C, Ritzel R. et al . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.  Am J Physiol (Endocrinol Metab). 1997;  273 E 981-988
    PubMedGoogle Scholar
  • 19 Willms B, Werner J, Holst J J, Ørskov C, Creutzfeldt W, Nauck M A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.  J Clin Endocrinol Metab. 1996;  81 327-332
    CrossrefPubMedGoogle Scholar
  • 20 Flint A, Raben A, Astrup A, Holst J J. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans.  J Clin Invest. 1998;  101 515-520
    CrossrefPubMedGoogle Scholar
  • 21 Gutzwiller J P, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D. et al . Glucagon-like peptide-1: a potent regulator of food intake in humans.  Gut. 1999;  44 81-86
    CrossrefPubMedGoogle Scholar
  • 22 Verdich C, Flint A, Gutzwiller J P, Naslund E, Beglinger C, Hellstrom P M. et al . A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.  J Clin Endocrinol Metab. 2001;  86(9) 4382-4389
    CrossrefPubMedGoogle Scholar
  • 23 Flint A, Raben A, Ersboll A K, Holst J J, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.  Int J Obes Relat Metab Disord. 2001;  25(6) 781-792
    PubMedGoogle Scholar
  • 24 Gutzwiller J P, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J. et al . Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.  Am J Physiol (Integr Regul Physiol). 1999;  276 R 1541-1544
    PubMedGoogle Scholar
  • 25 Toft-Nielsen M-B, Madsbad S, Holst J J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in Type 2 diabetic patients.  Diabetes Care. 1999;  22 1137-1143
    CrossrefPubMedGoogle Scholar
  • 26 Zander M, Madsbad S, Madsen J L, Holst J J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.  Lancet. 2002;  359 824-830
    CrossrefPubMedGoogle Scholar
  • 27 Nauck M A, Hompesch M, Filipicazak R, Le T DT, Nielsen L L, Zdravkovic M. et al . Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes (abstract).  Diabetes. 2004;  53 (Suppl. 2) A 83
    PubMedGoogle Scholar
  • 28 Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews D R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial.  Diabetes Care. 2004;  27 1335-1342
    CrossrefPubMedGoogle Scholar
  • 29 Meier J J, Gallwitz B, Schmidt W E, Nauck M A. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.  Eur J Pharmacol. 2002;  440(2 - 3) 269-279
    CrossrefPubMedGoogle Scholar
  • 30 Xu G, Stoffers D A, Habener J F, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.  Diabetes. 1999;  48 2270-2276
    CrossrefPubMedGoogle Scholar
  • 31 Stoffers D A, Kieffer T J, Hussain M A, Drucker D J, Bonner-Weir S, Habener J F. et al . Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.  Diabetes. 2000;  49 741-748
    CrossrefPubMedGoogle Scholar
  • 32 Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells.  Diabetes. 2001;  50 785-796
    CrossrefPubMedGoogle Scholar
  • 33 Rolin B, Larsen M O, Gotfredsen C F, Deacon C F, Carr R D, Wilken M. et al . The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.  Am J Physiol (Endocrinol Metab). 2002;  283 E 745-752
    PubMedGoogle Scholar
  • 34 Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.  Endocrinology. 2003;  144 1444-1455
    CrossrefPubMedGoogle Scholar
  • 35 Wettergren A. Glucagon-like peptide-1. Gastrointestinal function and possible mechanism of action.  Dan Med Bull. 2001;  48 (1) 19-28
    PubMedGoogle Scholar
  • 36 Rachman J, Gribble F M, Levy J C, Turner R C. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM.  Diabetologia. 1997;  40 205-211
    CrossrefPubMedGoogle Scholar
  • 37 Rachman J, Gribble F M, Barrow B A, Levy J C, Buchanan K D, Turner R C. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.  Diabetes. 1996;  45 1524-1530
    PubMedGoogle Scholar
  • 38 Toft-Nielsen M B, Madsbad S, Holst J J. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.  J Clin Endocrinol Metab. 2001;  86 3853-3860
    CrossrefPubMedGoogle Scholar
  • 39 Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.  Diabetes Care. 2001;  24 1416-1421
    PubMedGoogle Scholar
  • 40 Gutniak M K, Linde B, Holst J J, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.  Diabetes Care. 1994;  17 1039-1044
    CrossrefPubMedGoogle Scholar
  • 41 Ritzel R, Ørskov C, Holst J J, Nauck M A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.  Diabetologia. 1995;  38 720-725
    CrossrefPubMedGoogle Scholar
  • 42 Nauck M A, Wollschläger D, Werner J. , Holst JJ, Ørskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.  Diabetologia. 1996;  39 1546-1553
    CrossrefPubMedGoogle Scholar
  • 43 Zander M, Taskiran M, Toft-Nielsen M B, Madsbad S, Holst J J. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.  Diabetes Care. 2001;  24 720-725
    CrossrefPubMedGoogle Scholar
  • 44 Zander M, Christiansen A, Madsbad S, Holst J J. Additive effects of glucagon-like peptide-1 and pioglitazone in patients with type 2 diabetes.  Diabetes Care. 2004;  27 1910-1914
    CrossrefPubMedGoogle Scholar
  • 45 Deacon C F, Nauck M A, Toft-Nielsen M, Pridal L, Willms B, Host J J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2 diabetic patients and in healthy subjects.  Diabetes. 1995;  44 1126-1131
    CrossrefPubMedGoogle Scholar
  • 46 Åhren B, Larsson H, Holst J J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1997;  82 473-478
    CrossrefPubMedGoogle Scholar
  • 47 Vilsbøll T, Agersø H, Krarup T, Holst J J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.  J Clin Endocrinol Metab. 2003;  88 220-224
    CrossrefPubMedGoogle Scholar
  • 48 Deacon C F, Pridal L, Klarskov L, Olesen M, Holst J J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.  Am J Physiol (Endocrinol Metab). 1996;  271 E 458-464
    PubMedGoogle Scholar
  • 49 Mentlein R, Gallwitz B, Schmidt W E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum.  Eur J Biochem. 1993;  214 829-835
    CrossrefPubMedGoogle Scholar
  • 50 Deacon C F, Johnsen A H, Holst J J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.  J Clin Endocrinol Metab. 1995;  80 952-957
    CrossrefPubMedGoogle Scholar
  • 51 Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann D. Is GLP-1 (9-36)amide an endogenous antagonist at GLP-1 receptors? (abstract).  Digestion. 1994;  55 302
    PubMedGoogle Scholar
  • 52 Knudsen L B, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.  Eur J Pharmacol. 1996;  318 (2 - 3) 429-435
    CrossrefPubMedGoogle Scholar
  • 53 Deacon C F, Plamboeck A, Moller S, Holst J J. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.  Am J Physiol Endocrinol Metab. 2002;  282(4) E873-E879
    PubMedGoogle Scholar
  • 54 Vahl T P, Paty B W, Fuller B D, Prigeon R L, D’Alessio D A. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.  J Clin Endocrinol Metab. 2003;  88 1772-1779
    CrossrefPubMedGoogle Scholar
  • 55 Ørskov C, Andreasen J, Holst J J. All products of proglucagon are elevated in plasma of uremic patients.  J Clin Endocrinol Metab. 1992;  74 379-384
    CrossrefPubMedGoogle Scholar
  • 56 Meier J J, Nauck M A, Kranz D, Holst J J, Deacon C F, Gaeckler D. et al . Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.  Diabetes. 2004;  53 654-662
    CrossrefPubMedGoogle Scholar
  • 57 Vilsbøll T, Krarup T, Deacon C F, Madsbad S, Holst J J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.  Diabetes. 2001;  50 609-613
    PubMedGoogle Scholar
  • 58 Deacon C F, Wamberg S, Bie P, Hughes T E, Holst J J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.  J Endocrinol. 2002;  172 (2) 355-362
    CrossrefPubMedGoogle Scholar
  • 59 Nikolaidis L A, Mankad S, Sokos G G, Miske G, Shah A, Elahi D. et al . Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.  Circulation. 2004;  109 962-965. Epub 2004 Feb 23
    CrossrefPubMedGoogle Scholar
  • 60 Meier J J, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck M A. et al . Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.  Crit Care Med. 2004;  32 848-851
    CrossrefPubMedGoogle Scholar
  • 61 Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M. et al . Intensive insulin therapy in critically ill patients.  N Engl J Med. 2001;  345 1359-1367
    CrossrefPubMedGoogle Scholar
  • 62 Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus.  Diabetes/Metab Rev. 1992;  8 149-177
    PubMedGoogle Scholar
  • 63 Knapke C M, Owens J P, Mirtallo J M. Management of glucose abnormalities in patients receiving total parenteral nutrition.  Clin Pharm. 1989;  8 136-144
    PubMedGoogle Scholar
  • 64 Watters J M, Kirkpatrick S M, Hopbach D, Norris S B. Aging exaggerates the blood glucose response to total parenteral nutrition.  Can J Surg. 1996;  39 481-485
    PubMedGoogle Scholar
  • 65 McMahon M M. Management of hyperglycemia in hospitalized patients receiving parenteral nutrition.  Nutr Clin Pract. 1997;  12 35-38
    PubMedGoogle Scholar
  • 66 Nauck M A, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst J J. et al . Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.  Regul Pept. 2004;  118 89-97
    CrossrefPubMedGoogle Scholar
  • 67 Gutniak M K, Juntti-Berggren L, Hellstrom P M, Guenifi A, Holst J J, Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.  Diabetes Care. 1996;  19 857-863
    PubMedGoogle Scholar
  • 68 Todd J F, Wilding J P, Edwards C M, Khan F A, Ghatei M A, Bloom S R. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.  Eur J Clin Invest. 1997;  27 533-536
    CrossrefPubMedGoogle Scholar
  • 69 Nauck M, Kemmeries G, Grosser S, Ørskov C, Holst J J, Schmiegel W. Rapid tachyphylaxis for the deceleration of gastric emptying by exogenous GLP-1 (abstract).  Gastroenterol. 1997;  112 (Suppl.) A 797
    PubMedGoogle Scholar
  • 70 Nauck M A, Meier J J, Creutzfeldt W. Incretins and their analogues as new antidiabetic agents.  Drug News Perspect. 2003;  16 413-422
    CrossrefPubMedGoogle Scholar
  • 71 Meier J J, Gallwitz B, Nauck M A. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.  BioDrugs. 2003;  17 93-102
    CrossrefPubMedGoogle Scholar
  • 72 Holst J J. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential.  Trend Endocinol Metab. 1999;  10 229-235
    PubMedGoogle Scholar
  • 73 Drucker D J. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.  Curr Pharm Des. 2001;  7 (14) 1399-1412
    CrossrefPubMedGoogle Scholar
  • 74 Drucker D J. Biological actions and therapeutic potential of the glucagon-like peptides.  Gastroenterology. 2002;  122 531-544
    PubMedGoogle Scholar

Prof. Dr. med. M. A. Nauck

Diabeteszentrum Bad Lauterberg

Kirchberg 21 · 37431 Bad Lauterberg im Harz · Germany

Phone: +49 (524) 81-218

Fax: +49 (524) 81-398

Email: M.Nauck@diabeteszentrum.de